Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

Stopped Funder decision

Conditions

• Neuroendocrine Tumors
• Carcinoid Syndrome
• Diarrhea

Interventions

• DRUG: Telotristat ethyl
• DRUG: Peptide Receptor Radionuclide Therapy
• OTHER: Placebo

Sponsor

Chandrikha Chandrasekhara